Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,418.00-3.31%ETH$2,568.17-5.47%GOLD$4,096.50-2.16%OIL$90.16+0.81%
Smart Investors Daily
SID Premium
BioStem Technologies, Inc. logo

OTC · BSEM

BioStem Technologies, Inc.

Healthcare · Biotechnology

$2.47

Down-$0.29 (-10.34%)

Updated Oct 7, 2026, 4:05 AM

SID Score

2.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
70.33M
P/E ratio
3.5
Dividend yield
0.00%
52-week range
$2.25 – $5.44
Volume
128.62K
Avg. volume
68.56K

Price performance · BSEM

BSEM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

BSEM closed at $2.47 after 21 trading sessions, down 38.25% for the selected period.

Last close
$2.47
Period change
-38.25%
Period low
$2.47
Period high
$4.74
Daily close
View OHLC price history
BSEM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$2.76$2.79$2.45$2.47128.62K
Oct 5, 2026$2.74$2.8267$2.5815$2.755120.98K
Oct 2, 2026$3.03$3.0699$2.69$2.73158.1K
Oct 1, 2026$3.10$3.2405$3.04$3.0790.84K
Sep 30, 2026$3.80$3.8372$3.00$3.09332.9K
Sep 29, 2026$4.00$4.10$3.81$3.8349.91K
Sep 28, 2026$4.08$4.3219$3.85$4.05181.7K
Sep 25, 2026$3.85$4.28$3.81$4.14278.94K
Sep 24, 2026$3.78$4.0493$3.78$3.88150.5K
Sep 23, 2026$3.92$4.05$3.76$3.8084.03K
Sep 22, 2026$4.36$4.6138$3.95$3.98129.67K
Sep 21, 2026$5.20$5.247$4.40$4.40237.73K
Sep 18, 2026$4.25$5.44$4.24$4.74857.13K
Sep 17, 2026$4.18$4.50$4.06$4.36119.65K
Sep 16, 2026$3.96$4.34$3.96$4.0876.37K
Sep 15, 2026$4.15$4.35$3.90$4.01117.04K
Sep 14, 2026$4.41$4.50$4.16$4.21140.51K
Sep 11, 2026$4.23$4.45$4.17$4.31143.08K
Sep 10, 2026$4.13$4.30$4.13$4.17593.85K
Sep 9, 2026$4.05$4.30$4.04$4.21117.7K
Sep 8, 2026$3.88$4.65$3.865$4.00391.83K

Latest BSEM news

The latest Smart Investors Daily articles mentioning BSEM.

Stock researchCompany · Overview

BSEM research

Overview

Company profile and research snapshot.

Company profile

BIOSTEM TECHNOLOGIES NEW

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BSEM recent ratings
DateFirmRatingTarget
Nov 7, 2022Zacks Investment ResearchBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio

Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologiesPOMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the Unite

Yahoo · Sep 30, 2026

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company’s common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Ser

Yahoo · Sep 21, 2026

Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform

West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform. BioStem Technologies will utilize Terminal1’s integrated suite of shareholder intelligence, investor communications, and digital investor relations tools, giving the company a centralized platform to better understand its shareholder base, communicate with investors, and measure engagement

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By